Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of cevidoplenib in active rheumatoid arthritis despite conventional therapy
2018-003330-32Phase 2Completed
- Sponsor
- Oscotec Inc.
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cevidoplenib in rheumatoid arthritis (RA) (4 arms), sponsored by Oscotec Inc. Primary endpoint: Mean change from baseline in disease activity score for 28 joints using high-sensitivity C-reactive protein. Started May 2019; status: completed.
02
Drugs
cevidoplenib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-003330-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003330-32.